Open AccessBoceprevir early-access for advanced-fibrosis/cirrhosis in Asia-pacific hepatitis C virus genotype 1 non-responders/relapsers
Author(s) -
Wattana Sukeepaisarnjaroen,
Tri Pham,
Tawesak Tanwandee,
Saroja Nazareth,
Sam Galhenage,
Lindsay Mollison,
Leanne Totten,
Alan Wigg,
Rosalie Altus,
Anton Colman,
Brenda Morales,
Sue Mason,
Tracey Jones,
Nadine Leembruggen,
Vince Fragomelli,
Cheryl Sendall,
R Guan,
Dede Selamat Sutedja,
Soek Siam Tan,
Yock Young Dan,
Yin Mei Lee,
W Luman,
Eng Kiong Teo,
Yin Min Than,
Teerha Piratvisuth,
Seng Gee Lim
Publication year - 2015
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v21.i28.8660
Subject(s) - boceprevir , medicine , ribavirin , cirrhosis , gastroenterology , adverse effect , hepatitis c , hepatitis c virus , decompensation , pegylated interferon , immunology , virus
To examined the efficacy and safety of treatment with boceprevir, PEGylated-interferon and ribavirin (PR) in hepatitis C virus genotype 1 (HCVGT1) PR treatment-failures in Asia.